与索拉非尼相比,Tivozanib(盐酸替沃扎尼胶囊)的治疗普遍耐受性良好,安全性也较好。接受Tivozanib(盐酸替沃扎尼胶囊)治疗的84% (n = 146)的患者和接受索拉非尼治疗的94% (n = 160)的患者报告了治疗相关不良事件(TRAEs)。两组患者中,最常见的3级或4级不良事件是高血压。与接受Tivozanib(盐酸替沃扎尼胶囊)治疗相关的、最常见的不良事件为高血压(38%)、腹泻(33%)、疲劳(29%)和食欲下降(27%)。参考文献:1.AVEO Oncology Announces FDA Acceptance for Filing of a New Drug Application for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma. Published June 1, 2020. https://aveooncology.gcs-web.com/node/14681/pdf. Accessed June 1, 2020.2.Pal SK, Escudier B, Atkins MB, et al. TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC). Presented at: 2020 ASCO Virtual Program; May 27, 2020. Abstract 5062.